SCM
GILD icon

Springhouse Capital Management’s Gilead Sciences GILD Stock Holding History

Springhouse Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-243,000
Closed -$17.2M – 17
2017
Q2 		$17.2M Buy
243,000
+135,000
+125% +$8.98M 6.8% 6
2017
Q1 		$7.33M Buy
108,000
+15,000
+16% +$1.05M 3.09% 8
2016
Q4 		$6.66M Buy
+93,000
New +$6.91M 2.77% 8

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Springhouse Capital Management's GILD Position: Q3 2017 in Review

Springhouse Capital Management sold out of Gilead Sciences (GILD) in Q3 2017, closing a stake of 243,000 shares — an estimated $17.2M sold.

Springhouse Capital Management first reported a position in GILD in Q4 2016 and held it in 3 quarters. The position peaked at $17.2M in Q2 2017. 1,503 funds tracked by Wall St. Rank hold GILD as of Q3 2017.

  • Springhouse Capital Management reported no remaining Gilead Sciences position as of Q3 2017 after selling out during the quarter.
  • Springhouse Capital Management sold 243,000 Gilead Sciences shares in Q3 2017, an estimated $17.2M.
  • Springhouse Capital Management first reported a position in Gilead Sciences in Q4 2016 and held it in 3 quarters.
  • Springhouse Capital Management's Gilead Sciences position peaked at $17.2M in Q2 2017.
  • 1,503 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2017.

Based on Springhouse Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.